Compare WETH & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | SCNX |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 18.4M |
| IPO Year | 2020 | N/A |
| Metric | WETH | SCNX |
|---|---|---|
| Price | $1.39 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 52.0K | ★ 285.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $42,280,373.00 | N/A |
| Revenue This Year | N/A | $347.88 |
| Revenue Next Year | N/A | $744.44 |
| P/E Ratio | $2.34 | ★ N/A |
| Revenue Growth | ★ 6.48 | N/A |
| 52 Week Low | $0.76 | $0.37 |
| 52 Week High | $3.68 | $3.17 |
| Indicator | WETH | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 41.97 |
| Support Level | $1.22 | $0.37 |
| Resistance Level | $1.42 | $0.47 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 8.00 | 30.82 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.